AK119

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

AK119 is an investigational drug currently being studied in clinical trials for colorectal cancer. It is being evaluated in patients whose tumors are microsatellite stable (MSS), meaning they have specific genetic characteristics. The trials are exploring AK119 alone or in combination with another investigational drug called AK112, sometimes with or without standard chemotherapy drugs like 5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin. These trials are in early phases (Phase 1b/II) and are primarily focused on determining the safety and appropriate dosage of AK119, as well as looking for early signs of effectiveness in patients who have not responded well to standard treatments or are receiving first-line treatment. The trials are being conducted in China and involve patients with advanced colorectal cancer.

Mechanism of Action

AK119 is being investigated as a potential treatment for colorectal cancer. The specific way it works (its mechanism of action) is still being studied in clinical trials. Researchers are working to understand how it affects cancer cells and whether it can help control tumor growth, especially in MSS colorectal cancer.

Side Effects

Because AK119 is an investigational drug in early-phase clinical trials The full range of potential side effects is still being evaluated. Information about side effects is being collected during the trials to assess the drug's safety profile. Common side effects observed in early trials for similar drugs or combinations can include fatigue Nausea Diarrhea And changes in blood counts But specific data for AK119 is still emerging.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05846867 Phase 1
Active, not recruiting
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
China